[go: up one dir, main page]

MX2020003511A - Formulaciones orales de bendamustina. - Google Patents

Formulaciones orales de bendamustina.

Info

Publication number
MX2020003511A
MX2020003511A MX2020003511A MX2020003511A MX2020003511A MX 2020003511 A MX2020003511 A MX 2020003511A MX 2020003511 A MX2020003511 A MX 2020003511A MX 2020003511 A MX2020003511 A MX 2020003511A MX 2020003511 A MX2020003511 A MX 2020003511A
Authority
MX
Mexico
Prior art keywords
bendamustine formulations
oral bendamustine
oral
formulations
empty
Prior art date
Application number
MX2020003511A
Other languages
English (en)
Inventor
Wolfgang Richter
Original Assignee
Tube Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tube Pharmaceuticals Gmbh filed Critical Tube Pharmaceuticals Gmbh
Publication of MX2020003511A publication Critical patent/MX2020003511A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral que comprende bendamustina en combinación con una ciclodextrina modificada, tal como, por ejemplo, metil-ß-ciclodextrina o hidroxipropil-ß-ciclodextrina. Se ha encontrado sorprendentemente en el contexto de la invención 5 que tales composiciones exhiben una biodisponibilidad oral mejorada en gran medida, lo que las hace particularmente convenientes para aplicación terapéutica oral, por ejemplo, en el tratamiento del cáncer.
MX2020003511A 2017-10-05 2018-10-05 Formulaciones orales de bendamustina. MX2020003511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17194987 2017-10-05
PCT/EP2018/077214 WO2019068904A1 (en) 2017-10-05 2018-10-05 ORAL ADMINISTRATION OF BENDAMUSTINE FORMULATIONS

Publications (1)

Publication Number Publication Date
MX2020003511A true MX2020003511A (es) 2020-07-22

Family

ID=60022004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003511A MX2020003511A (es) 2017-10-05 2018-10-05 Formulaciones orales de bendamustina.

Country Status (14)

Country Link
US (2) US20200246312A1 (es)
EP (1) EP3691637A1 (es)
JP (1) JP7267290B2 (es)
KR (3) KR20220138420A (es)
CN (1) CN111201019A (es)
AU (1) AU2018346395A1 (es)
BR (1) BR112020006360A2 (es)
CA (1) CA3078290A1 (es)
IL (1) IL273644A (es)
MX (1) MX2020003511A (es)
RU (1) RU2020115024A (es)
SG (1) SG11202003098WA (es)
WO (1) WO2019068904A1 (es)
ZA (1) ZA202002129B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021080955A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
WO2021203377A1 (zh) * 2020-04-09 2021-10-14 比卡生物科技（广州）有限公司 苯达莫司汀组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
US20120003305A1 (en) 2008-12-03 2012-01-05 Astellas Deutschland Gmbh Oral Dosage Forms Of Bendamustine
UA107186C2 (xx) 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
RU2591804C2 (ru) 2009-02-25 2016-07-20 Супратек Фарма, Инк. Композиции бендамустина и циклополисахарида
EP2424506A1 (en) 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
US11020363B2 (en) * 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
CN101606934B (zh) 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CN102351799B (zh) 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica

Also Published As

Publication number Publication date
SG11202003098WA (en) 2020-05-28
JP2020536126A (ja) 2020-12-10
BR112020006360A2 (pt) 2020-09-24
CN111201019A (zh) 2020-05-26
ZA202002129B (en) 2023-10-25
JP7267290B2 (ja) 2023-05-01
RU2020115024A (ru) 2021-11-08
KR20200066657A (ko) 2020-06-10
KR20220138420A (ko) 2022-10-12
US20200246312A1 (en) 2020-08-06
AU2018346395A1 (en) 2020-04-30
WO2019068904A1 (en) 2019-04-11
KR20240134053A (ko) 2024-09-05
US20240390331A1 (en) 2024-11-28
KR102450975B1 (ko) 2022-10-07
RU2020115024A3 (es) 2022-03-17
CA3078290A1 (en) 2019-04-11
IL273644A (en) 2020-05-31
EP3691637A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
MX2020003760A (es) Formulaciones de niraparib.
IL273541A (en) formulations
IL268697A (en) Formulations
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
GB2559774B (en) Oral cannabinoid formulations
MX2019004744A (es) Composicion oral de fases multiples para suministrar agentes activos para el cuidado bucal.
IL269630A (en) Niraprib formulations
GB201611547D0 (en) Oral cannabinoid formulations
IL269621A (en) Niraparib formulations
MX2020004424A (es) Formulacion aerosolizable.
MX2020003712A (es) Union giratoria de pasaje multiple.
PL3582627T3 (pl) Formulacje stabilne podczas przechowywania
ZA201807730B (en) An oral care composition
MX2020003617A (es) Dispositivo de preparacion de cables.
GB201707189D0 (en) Novel formulations
SG11202003537TA (en) Linezolid formulations
GB201707188D0 (en) Novel formulations
MX2019015167A (es) Farmacos antivirales.
MX2020004422A (es) Formulacion vaporizable saborizada.
MX2020003511A (es) Formulaciones orales de bendamustina.
MX2020003440A (es) Red de seguridad.
GB201707187D0 (en) Novel formulations
MX2020003703A (es) Composiciones de sabor.
MX2020003537A (es) Aplicador con una camara integrada.
MX2020004664A (es) Dispositivo generador de humo mejorado.